Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
8.89
+0.33 (3.86%)
At close: May 17, 2024, 4:00 PM
8.90
+0.01 (0.11%)
After-hours: May 17, 2024, 6:12 PM EDT
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ACRV stock have an average target of 24.14, with a low estimate of 17 and a high estimate of 30. The average target predicts an increase of 171.54% from the current stock price of 8.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ACRV stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 3 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 8 | 6 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
BMO Capital | BMO Capital | Buy Reiterates $25 | Buy | Reiterates | $25 | +181.21% | May 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +147.47% | May 14, 2024 |
Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 29, 2024 |
BMO Capital | BMO Capital | Buy Maintains $18 → $25 | Buy | Maintains | $18 → $25 | +181.21% | Apr 26, 2024 |
JMP Securities | JMP Securities | Buy Maintains $14 → $17 | Buy | Maintains | $14 → $17 | +91.23% | Apr 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.03M
EPS This Year
-3.57
from -2.74
EPS Next Year
-3.38
from -3.57
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 5.3M | 55.0M | 180.3M | 363.0M |
Avg | n/a | 1.0M | 18.1M | 67.1M | 147.1M |
Low | n/a | n/a | n/a | 3.9M | 25.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 5,231.4% | 896.8% | 440.8% |
Avg | - | - | 1,652.8% | 271.1% | 119.0% |
Low | - | - | - | -78.3% | -62.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -3.15 | -2.49 | -2.10 | -1.32 | -1.09 |
Avg | -3.57 | -3.38 | -2.99 | -2.64 | -2.90 |
Low | -4.33 | -4.30 | -4.26 | -4.75 | -4.56 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.